The effects of gonadotropin treatment on the immunological features of male patients with idiopathic hypogonadotropic hypogonadism.

Yesilova Z, Ozata M, Kocar IH, Turan M, Pekel A, Sengul A, Ozdemír IC

The Journal of clinical endocrinology and metabolism1 Jan 2000Cited by 54 (Europe PMC)

PMID10634365DOI10.1210/jcem.85.1.6226PepBankPUB-10634365

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone12

In this study, hCG (human chorionic gonadotropin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking hCG (human chorionic gonadotropin).

01HumanNot a test of hCG (human chorionic gonadotropin) aloneNon-randomized trialEfficacy outcome
In men with IHH, hMG/hCG reduced IgA compared with pretreatment levels.
In plain wordsIn men with IHH, hMG/hCG reduced IgA compared with pretreatment levels.
Peptide
hCG (human chorionic gonadotropin)
Outcome
DecreaseIgA
Study
n = 29
Comparator
Pretreatment levels
Outcome group
Immune response · Immune and inflammation
Measurements
P value for IgA after treatment versus pretreatment
< 0.001 p value
men with IHH, after 6 months of hMG/hCG versus pretreatment
Source sentences
Summary
After treatment, all Igs (P<0.001), C3c (P<0.01), and IL-2 and IL-4 levels (P<0.005) were decreased significantly compared to pretreatment levels.
3 context sentences(design, population, supporting numbers)
Summary · context
Thus, the objective of this study was to evaluate the levels of selected soluble immune parameters [IgA, IgG, IgM, C3c, C4, interleukin-2 (IL-2), and IL-4], the CD4+/CD8 ratio, and counts of total lymphocyte and some subpopulation of lymphocytes (CD3+, CD4+, CD8+, and CD19+ cells) before and after g…
Summary · context
Twenty-nine IHH patients and 19 age-matched healthy controls were included in the study.
Summary · context
The patients were treated with human menopausal gonadotropin/hCG for 6 months.
In this study, hCG (human chorionic gonadotropin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking hCG (human chorionic gonadotropin).
Report a problemFND-1063436501
02HumanNot a test of hCG (human chorionic gonadotropin) aloneNon-randomized trialEfficacy outcome
In men with IHH, hMG/hCG reduced IgG compared with pretreatment levels.
In plain wordsIn men with IHH, hMG/hCG reduced IgG compared with pretreatment levels.
Peptide
hCG (human chorionic gonadotropin)
Outcome
DecreaseIgG
Study
n = 29
Comparator
Pretreatment levels
Outcome group
Immune response · Immune and inflammation
Measurements
P value for IgG after treatment versus pretreatment
< 0.001 p value
men with IHH, after 6 months of hMG/hCG versus pretreatment
Source sentences
Summary
After treatment, all Igs (P<0.001), C3c (P<0.01), and IL-2 and IL-4 levels (P<0.005) were decreased significantly compared to pretreatment levels.
3 context sentences(design, population, supporting numbers)
Summary · context
Thus, the objective of this study was to evaluate the levels of selected soluble immune parameters [IgA, IgG, IgM, C3c, C4, interleukin-2 (IL-2), and IL-4], the CD4+/CD8 ratio, and counts of total lymphocyte and some subpopulation of lymphocytes (CD3+, CD4+, CD8+, and CD19+ cells) before and after g…
Summary · context
Twenty-nine IHH patients and 19 age-matched healthy controls were included in the study.
Summary · context
The patients were treated with human menopausal gonadotropin/hCG for 6 months.
In this study, hCG (human chorionic gonadotropin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking hCG (human chorionic gonadotropin).
Report a problemFND-1063436502
03HumanNot a test of hCG (human chorionic gonadotropin) aloneNon-randomized trialEfficacy outcome
In men with IHH, hMG/hCG reduced IgM compared with pretreatment levels.
In plain wordsIn men with IHH, hMG/hCG reduced IgM compared with pretreatment levels.
Peptide
hCG (human chorionic gonadotropin)
Outcome
DecreaseIgM
Study
n = 29
Comparator
Pretreatment levels
Outcome group
Immune response · Immune and inflammation
Measurements
P value for IgM after treatment versus pretreatment
< 0.001 p value
men with IHH, after 6 months of hMG/hCG versus pretreatment
Source sentences
Summary
After treatment, all Igs (P<0.001), C3c (P<0.01), and IL-2 and IL-4 levels (P<0.005) were decreased significantly compared to pretreatment levels.
3 context sentences(design, population, supporting numbers)
Summary · context
Thus, the objective of this study was to evaluate the levels of selected soluble immune parameters [IgA, IgG, IgM, C3c, C4, interleukin-2 (IL-2), and IL-4], the CD4+/CD8 ratio, and counts of total lymphocyte and some subpopulation of lymphocytes (CD3+, CD4+, CD8+, and CD19+ cells) before and after g…
Summary · context
Twenty-nine IHH patients and 19 age-matched healthy controls were included in the study.
Summary · context
The patients were treated with human menopausal gonadotropin/hCG for 6 months.
In this study, hCG (human chorionic gonadotropin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking hCG (human chorionic gonadotropin).
Report a problemFND-1063436503
04HumanNot a test of hCG (human chorionic gonadotropin) aloneNon-randomized trialEfficacy outcome
In men with IHH, hMG/hCG reduced C3c compared with pretreatment levels.
In plain wordsIn men with IHH, hMG/hCG reduced C3c compared with pretreatment levels.
Peptide
hCG (human chorionic gonadotropin)
Outcome
DecreaseC3c
Study
n = 29
Comparator
Pretreatment levels
Outcome group
Immune response · Immune and inflammation
Measurements
P value for C3c after treatment versus pretreatment
< 0.01 p value
men with IHH, after 6 months of hMG/hCG versus pretreatment
Source sentences
Summary
After treatment, all Igs (P<0.001), C3c (P<0.01), and IL-2 and IL-4 levels (P<0.005) were decreased significantly compared to pretreatment levels.
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty-nine IHH patients and 19 age-matched healthy controls were included in the study.
Summary · context
The patients were treated with human menopausal gonadotropin/hCG for 6 months.
In this study, hCG (human chorionic gonadotropin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking hCG (human chorionic gonadotropin).
Report a problemFND-1063436504
05HumanNot a test of hCG (human chorionic gonadotropin) aloneNon-randomized trialEfficacy outcome
In men with IHH, hMG/hCG reduced IL-2 compared with pretreatment levels.
In plain wordsIn men with IHH, hMG/hCG reduced IL-2 compared with pretreatment levels.
Peptide
hCG (human chorionic gonadotropin)
Outcome
DecreaseIL-2
Study
n = 29
Comparator
Pretreatment levels
Outcome group
Immune response · Immune and inflammation
Measurements
P value for IL-2 after treatment versus pretreatment
< 0.005 p value
men with IHH, after 6 months of hMG/hCG versus pretreatment
Source sentences
Summary
After treatment, all Igs (P<0.001), C3c (P<0.01), and IL-2 and IL-4 levels (P<0.005) were decreased significantly compared to pretreatment levels.
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty-nine IHH patients and 19 age-matched healthy controls were included in the study.
Summary · context
The patients were treated with human menopausal gonadotropin/hCG for 6 months.
In this study, hCG (human chorionic gonadotropin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking hCG (human chorionic gonadotropin).
Report a problemFND-1063436505
06HumanNot a test of hCG (human chorionic gonadotropin) aloneNon-randomized trialEfficacy outcome
In men with IHH, hMG/hCG reduced IL-4 compared with pretreatment levels.
In plain wordsIn men with IHH, hMG/hCG reduced IL-4 compared with pretreatment levels.
Peptide
hCG (human chorionic gonadotropin)
Outcome
DecreaseIL-4
Study
n = 29
Comparator
Pretreatment levels
Outcome group
Immune response · Immune and inflammation
Measurements
P value for IL-4 after treatment versus pretreatment
< 0.005 p value
men with IHH, after 6 months of hMG/hCG versus pretreatment
Source sentences
Summary
After treatment, all Igs (P<0.001), C3c (P<0.01), and IL-2 and IL-4 levels (P<0.005) were decreased significantly compared to pretreatment levels.
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty-nine IHH patients and 19 age-matched healthy controls were included in the study.
Summary · context
The patients were treated with human menopausal gonadotropin/hCG for 6 months.
In this study, hCG (human chorionic gonadotropin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking hCG (human chorionic gonadotropin).
Report a problemFND-1063436506
07HumanNot a test of hCG (human chorionic gonadotropin) aloneNon-randomized trialEfficacy outcome
In men with IHH, lymphocyte count decreased after hMG/hCG treatment.
In plain wordsIn men with IHH, lymphocyte count decreased after hMG/hCG compared with pretreatment.
Peptide
hCG (human chorionic gonadotropin)
Outcome
DecreaseLymphocyte count
Study
n = 29
Comparator
Pretreatment levels
Outcome group
Immune response · Immune and inflammation
Measurements
P value for Lymphocyte count after treatment versus pretreatment
< 0.001 p value
men with IHH, after 6 months of hMG/hCG versus pretreatment
Source sentences
Summary
After treatment, the lymphocyte count (P<0.001); CD3+ (P<0.01), CD4+ (P<0.001), and CD19+ (P<0.005) cells; and the CD4-/CD8+ ratio (P<0.001) were decreased, but CD8+ cells were increased significantly (P<0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty-nine IHH patients and 19 age-matched healthy controls were included in the study.
Summary · context
The patients were treated with human menopausal gonadotropin/hCG for 6 months.
In this study, hCG (human chorionic gonadotropin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking hCG (human chorionic gonadotropin).
Report a problemFND-1063436507
08HumanNot a test of hCG (human chorionic gonadotropin) aloneNon-randomized trialEfficacy outcome
In men with IHH, CD3+ cells decreased after hMG/hCG treatment.
In plain wordsIn men with IHH, CD3+ cells decreased after hMG/hCG compared with pretreatment.
Peptide
hCG (human chorionic gonadotropin)
Outcome
DecreaseCD3+ cells
Study
n = 29
Comparator
Pretreatment levels
Outcome group
Immune response · Immune and inflammation
Measurements
P value for CD3+ cells after treatment versus pretreatment
< 0.01 p value
men with IHH, after 6 months of hMG/hCG versus pretreatment
Source sentences
Summary
After treatment, the lymphocyte count (P<0.001); CD3+ (P<0.01), CD4+ (P<0.001), and CD19+ (P<0.005) cells; and the CD4-/CD8+ ratio (P<0.001) were decreased, but CD8+ cells were increased significantly (P<0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty-nine IHH patients and 19 age-matched healthy controls were included in the study.
Summary · context
The patients were treated with human menopausal gonadotropin/hCG for 6 months.
In this study, hCG (human chorionic gonadotropin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking hCG (human chorionic gonadotropin).
Report a problemFND-1063436508
09HumanNot a test of hCG (human chorionic gonadotropin) aloneNon-randomized trialEfficacy outcome
In men with IHH, CD4+ cells decreased after hMG/hCG treatment.
In plain wordsIn men with IHH, CD4+ cells decreased after hMG/hCG compared with pretreatment.
Peptide
hCG (human chorionic gonadotropin)
Outcome
DecreaseCD4+ cells
Study
n = 29
Comparator
Pretreatment levels
Outcome group
Immune response · Immune and inflammation
Measurements
P value for CD4+ cells after treatment versus pretreatment
< 0.001 p value
men with IHH, after 6 months of hMG/hCG versus pretreatment
Source sentences
Summary
After treatment, the lymphocyte count (P<0.001); CD3+ (P<0.01), CD4+ (P<0.001), and CD19+ (P<0.005) cells; and the CD4-/CD8+ ratio (P<0.001) were decreased, but CD8+ cells were increased significantly (P<0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty-nine IHH patients and 19 age-matched healthy controls were included in the study.
Summary · context
The patients were treated with human menopausal gonadotropin/hCG for 6 months.
In this study, hCG (human chorionic gonadotropin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking hCG (human chorionic gonadotropin).
Report a problemFND-1063436509
10HumanNot a test of hCG (human chorionic gonadotropin) aloneNon-randomized trialEfficacy outcome
In men with IHH, CD19+ cells decreased after hMG/hCG treatment.
In plain wordsIn men with IHH, CD19+ cells decreased after hMG/hCG compared with pretreatment.
Peptide
hCG (human chorionic gonadotropin)
Outcome
DecreaseCD19+ cells
Study
n = 29
Comparator
Pretreatment levels
Outcome group
Immune response · Immune and inflammation
Measurements
P value for CD19+ cells after treatment versus pretreatment
< 0.005 p value
men with IHH, after 6 months of hMG/hCG versus pretreatment
Source sentences
Summary
After treatment, the lymphocyte count (P<0.001); CD3+ (P<0.01), CD4+ (P<0.001), and CD19+ (P<0.005) cells; and the CD4-/CD8+ ratio (P<0.001) were decreased, but CD8+ cells were increased significantly (P<0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty-nine IHH patients and 19 age-matched healthy controls were included in the study.
Summary · context
The patients were treated with human menopausal gonadotropin/hCG for 6 months.
In this study, hCG (human chorionic gonadotropin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking hCG (human chorionic gonadotropin).
Report a problemFND-1063436510
11HumanNot a test of hCG (human chorionic gonadotropin) aloneNon-randomized trialEfficacy outcome
In men with IHH, the reported CD4-/CD8+ ratio decreased after hMG/hCG treatment.
In plain wordsIn men with IHH, the reported CD4-/CD8+ ratio decreased after hMG/hCG compared with pretreatment.
Peptide
hCG (human chorionic gonadotropin)
Outcome
DecreaseCD4-/CD8+ ratio
Study
n = 29
Comparator
Pretreatment levels
Outcome group
Immune response · Immune and inflammation
Measurements
P value for CD4-/CD8+ ratio after treatment versus pretreatment
< 0.001 p value
men with IHH, after 6 months of hMG/hCG versus pretreatment
Source sentences
Summary
After treatment, the lymphocyte count (P<0.001); CD3+ (P<0.01), CD4+ (P<0.001), and CD19+ (P<0.005) cells; and the CD4-/CD8+ ratio (P<0.001) were decreased, but CD8+ cells were increased significantly (P<0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty-nine IHH patients and 19 age-matched healthy controls were included in the study.
Summary · context
The patients were treated with human menopausal gonadotropin/hCG for 6 months.
In this study, hCG (human chorionic gonadotropin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking hCG (human chorionic gonadotropin).
Report a problemFND-1063436511
12HumanNot a test of hCG (human chorionic gonadotropin) aloneNon-randomized trialEfficacy outcome
In men with IHH, CD8+ cells increased after hMG/hCG treatment.
In plain wordsIn men with IHH, CD8+ cells increased after hMG/hCG compared with pretreatment.
Peptide
hCG (human chorionic gonadotropin)
Outcome
IncreaseCD8+ cells
Study
n = 29
Comparator
Pretreatment levels
Outcome group
Immune response · Immune and inflammation
Measurements
P value for CD8+ cells after treatment versus pretreatment
< 0.001 p value
men with IHH, after 6 months of hMG/hCG versus pretreatment
Source sentences
Summary
After treatment, the lymphocyte count (P<0.001); CD3+ (P<0.01), CD4+ (P<0.001), and CD19+ (P<0.005) cells; and the CD4-/CD8+ ratio (P<0.001) were decreased, but CD8+ cells were increased significantly (P<0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty-nine IHH patients and 19 age-matched healthy controls were included in the study.
Summary · context
The patients were treated with human menopausal gonadotropin/hCG for 6 months.
In this study, hCG (human chorionic gonadotropin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking hCG (human chorionic gonadotropin).
Report a problemFND-1063436512

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.